Skip Navigation

Advertise|Press|Contact|FAQ|CWConnect

Bookmark/Print/Share

Home » Clinical Trials » Fallopian Tube Cancer

Trial Information

Irinotecan and Bevacizumab for Recurrent Ovarian Cancer

Official Title: Phase II Study of Irinotecan in Combination With Bevacizumab for the Treatment of Recurrent Ovarian Cancer.

Summary

The purpose of the study is to evaluate the efficacy and toxicity of irinotecan in the treatment of women with recurrent epithelial ovarian cancer or primary peritoneal cancer when combined with bevacizumab.

Phase: Phase 2

Sponsor: New York University School of Medicine

Overall Contacts:

Franco Muggia, MD
212-263-6485

Yan Makeyev, MD
Phone: 212-263-6485

Locations (2)

Country State City Zip Facility and Contact
United States New York New York 10016 New York University Clinical Cancer Center
United States New York New York 10016 Bellevue Hospital Center (NYU Langone Medical Center affiliate)

NCT ID:NCT01091259

Date Last Changed: April 8, 2013